Luminex Corp: (NASD: LMNX)
$18.41
0.30 (1.66%)
Volume 323,927
May 17 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 18.22 - 18.59 |
| 52wk Low - High | 15.39 - 25.79 |
| Previous Close | 18.11 |
| Avg. Volume | 221,296 |
| Industry | MED INSTRUMENTS |
| Market Cap | 767.11 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.65 |
| PE (Forward) | 55.79 |
| Current Year Est. | 0.33 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
114 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | 55.79 |
| PEG Ratio | 2.99 |
| Current Year Est. | 0.33 |
| Current Quarter Estimate | 0.10 |
| Most Accurate Estimate | 0.10 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 08-05-2013 |
| EPS Last Year | 0.37 |
| Expected Earnings Growth | 18.67% |
Company Description
Luminex Corporation has developed, manufactures and markets a proprietary technology that simplifies biological testing for the life sciences industry. This industry depends on a broad range of tests, called bioassays, to discover new drugs, identify new genes or simply monitor blood cholesterol levels. The LabMAP system simultaneously performs up to 100 bioassays on a single drop of fluid.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | 0.10 | 0.11 | 0.33 | 0.55 |
| Number of Estimates | 5 | 5 | 3 | 5 |
| Low Estimate | 0.09 | 0.09 | 0.25 | 0.46 |
| High Estimate | 0.11 | 0.13 | 0.48 | NA |
| Year Ago EPS | 0.07 | 0.04 | 0.39 | 0.33 |
| EPS Growth | 42.86% | 165.00% | -15.38% | 66.67% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| LUMINEX CORP | LMNX | 18.41 | |
|
| NATUS MEDICAL | BABY | 14.36 | |
|
| CRYOLIFE INC | CRY | 6.34 | |
|
| DELCATH SYS INC | DCTH | 0.41 | |
|
| GLOBUS MEDICAL | GMED | 15.69 | |
|
| HEARTWARE INTL | HTWR | 99.19 | |
|
| MELA SCIENCES | MELA | 1.07 | |
|
| OXYSURE SYSTEMS | OXYS | 0.90 | |
|
| PACIFIC BIOSCI | PACB | 2.42 | |
|
| SUNSHINE HEART | SSH | 5.49 | |
|
Sector:Medical>> Industry:MED INSTRUMENTS
COMPARE TICKER vs. Its Peers
Zacks Commentary
Luminex Beats 1Q Earnings Est.
May 01, 2013
FDA Nod for Luminex Offering
Apr 19, 2013
Merck-Luminex' Alzheimer's Collaboration
Mar 19, 2013
Luminex Beats EPS, Profits Up
Feb 05, 2013
Luminex Wins FDA Clearance
Jan 16, 2013
Luminex Retained at Neutral
Dec 18, 2012
Luminex Misses Ests., Trims Outlook
Oct 30, 2012
Luminex Remains Neutral
Sep 17, 2012
Financials
| EPS TTM | 0.37 |
| Sales | 203 |
| Net Income | 6 |
| Price/Earnings | 49.76 |
| Price/Book | 3.03 |
| Price/Cash Flow | 25.06 |
| Price/Sales | 3.70 |
News
Luminex Earnings In Retrospect: Up 12.1% in the Last 19 Days (LMNX) - Financial News Network Online - Earnings Lookback
May 18, 2013
WALTER G. LOEWENBAUM II of Luminex Corporation (LMNX)-Nasdaq bought Shares of LMNX - M2
May 17, 2013
BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector - GuruFocus
May 14, 2013
Luminex Makes a Move: Up 1.6% - Financial News Network Online - Market Movers
May 14, 2013
Luminex Makes a Move: Up 1.3% - Financial News Network Online - Market Movers
May 10, 2013
Luminex Corporation To Present At Upcoming Investment Conferences - Pr Newswire
May 7, 2013
Monday 5/6 Insider Buying Report: LMNX, NEM - Marketnewsvideo.Com
May 6, 2013
Illumina and Other Bargain Biotech Stocks Worth a Look Now - Benzinga
May 1, 2013
Broker Recommendations
| Current ABR | 2.50 |
| ABR (Last Week) | 2.50 |
| # of recs in ABR | 8 |
| Average Target Price | 19.86 |
| Industry Rank by ABR | 114 out of 265 |
| Rank in Industry | 10 out of 52 |
